FOCU.SE is a national clinical trial coordinated by Edvard Abel at Sahlgrenska University Hospital in Gothenburg, Sweden. The trial was officially launched under the Testbed Sweden Precision Health Cancer initiative. This study aims to offer more cancer patients access to genomically-informed treatments, even beyond current drug indications.

Backed by a 44 million SEK investment from the Swedish government, FOCU.SE leverages Sweden’s robust life sciences infrastructure and regional genomic medicine centers. It builds on the success of DRUP-like trials and integrates digital Molecular Tumor Boards to support real-time, collaborative treatment decisions.

For the PRIME-ROSE community, FOCU.SE represents a major step forward in our shared mission to repurpose cancer medicines and harmonize access to precision oncology across Europe. The study’s patient-centered design, including early involvement of patient councils, aligns with PRIME-ROSE’s commitment to inclusive and impactful cancer research.

‍

📎 Learn more:

• FOCUS.SE
• New clinical study will provide more cancer patients with targeted treatment
• Ny nationell cancerstudie ska ge fler patienter tillgång till precisionsmedicin

‍